197 related articles for article (PubMed ID: 29249543)
1. An updated influenza A(H3N2) vaccine generates limited antibody responses to previously encountered antigens in children.
Florek KR; Campos LM; Braun KM; McLean HQ; King JP; Flannery B; Belongia EA; Friedrich TC
Vaccine; 2018 Jan; 36(5):758-764. PubMed ID: 29249543
[TBL] [Abstract][Full Text] [Related]
2. Neutralizing Antibody Responses to Antigenically Drifted Influenza A(H3N2) Viruses among Children and Adolescents following 2014-2015 Inactivated and Live Attenuated Influenza Vaccination.
Levine MZ; Martin JM; Gross FL; Jefferson S; Cole KS; Archibald CA; Nowalk MP; Susick M; Moehling K; Spencer S; Chung JR; Flannery B; Zimmerman RK
Clin Vaccine Immunol; 2016 Oct; 23(10):831-839. PubMed ID: 27558294
[TBL] [Abstract][Full Text] [Related]
3. Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses.
Allen JD; Jang H; DiNapoli J; Kleanthous H; Ross TM
J Virol; 2019 Feb; 93(3):. PubMed ID: 30429350
[TBL] [Abstract][Full Text] [Related]
4. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
[TBL] [Abstract][Full Text] [Related]
5. Influence of pre-existing hemagglutination inhibition titers against historical influenza strains on antibody response to inactivated trivalent influenza vaccine in adults 50-80 years of age.
Ross TM; Lin CJ; Nowalk MP; Huang HH; Spencer SM; Shay DK; Sambhara S; Sundaram ME; Friedrich T; Sauereisen S; Bloom CE; Zimmerman RK
Hum Vaccin Immunother; 2014; 10(5):1195-203. PubMed ID: 24614078
[TBL] [Abstract][Full Text] [Related]
6. Trivalent influenza vaccine-induced antibody response to circulating influenza a (H3N2) viruses in 2010/11 and 2011/12 seasons.
Hiroi S; Morikawa S; Nakata K; Maeda A; Kanno T; Irie S; Ohfuji S; Hirota Y; Kase T
Hum Vaccin Immunother; 2015; 11(2):386-90. PubMed ID: 25692378
[TBL] [Abstract][Full Text] [Related]
7. Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses.
Ansaldi F; Canepa P; Ceravolo A; Valle L; de Florentiis D; Oomen R; Vogel FR; Denis M; Samson SI; Icardi G
Vaccine; 2012 Apr; 30(18):2908-13. PubMed ID: 22342501
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Heterologous Prime-Boost Vaccination with H3N2 Influenza Viruses in Pre-Immune Individuals: Studies in the Pig Model.
Chepkwony S; Parys A; Vandoorn E; Chiers K; Van Reeth K
Viruses; 2020 Sep; 12(9):. PubMed ID: 32882956
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis.
Ruiz-Palacios GM; Leroux-Roels G; Beran J; Devaster JM; Esen M; Launay O; McElhaney JE; van Essen GA; Benoit A; Claeys C; Dewé W; Durand C; Duval X; Falsey AR; Feldman G; Galtier F; Gervais P; Hwang SJ; McNeil S; Richardus JH; Trofa A; Oostvogels L;
Hum Vaccin Immunother; 2016 Dec; 12(12):3043-3055. PubMed ID: 27690762
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents.
Munoz FM; Anderson EJ; Bernstein DI; Harrison CJ; Pahud B; Anderson E; Creech CB; Berry AA; Kotloff KL; Walter EB; Atmar RL; Bellamy AR; Chang S; Keitel WA
Vaccine; 2019 Aug; 37(36):5161-5170. PubMed ID: 31375440
[TBL] [Abstract][Full Text] [Related]
11. Differential Effects of Prior Influenza Exposures on H3N2 Cross-reactivity of Human Postvaccination Sera.
Xie H; Li L; Ye Z; Li X; Plant EP; Zoueva O; Zhao Y; Jing X; Lin Z; Kawano T; Chiang MJ; Finch CL; Kosikova M; Zhang A; Zhu Y; Wan XF
Clin Infect Dis; 2017 Jul; 65(2):259-267. PubMed ID: 28369230
[TBL] [Abstract][Full Text] [Related]
12. Immunological persistence of a seasonal influenza vaccine in people more than 3 years old.
Bai Y; Shi N; Lu Q; Yang L; Wang Z; Li L; Han H; Zheng D; Luo F; Zhang Z; Ai X
Hum Vaccin Immunother; 2015; 11(7):1648-53. PubMed ID: 26083828
[TBL] [Abstract][Full Text] [Related]
13. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with 2014-15 Seasonal Inactivated Influenza Vaccine Elicits Cross-Reactive Anti-HA Antibodies with Strong ADCC Against Antigenically Drifted Circulating H3N2 Virus in Humans.
Zhong W; Gross FL; Holiday C; Jefferson SN; Bai Y; Liu F; Katz JM; Levine MZ
Viral Immunol; 2016 May; 29(4):259-62. PubMed ID: 26950058
[TBL] [Abstract][Full Text] [Related]
15. Antibodies Against Egg- and Cell-Grown Influenza A(H3N2) Viruses in Adults Hospitalized During the 2017-2018 Influenza Season.
Levine MZ; Martin ET; Petrie JG; Lauring AS; Holiday C; Jefferson S; Fitzsimmons WJ; Johnson E; Ferdinands JM; Monto AS
J Infect Dis; 2019 May; 219(12):1904-1912. PubMed ID: 30721982
[TBL] [Abstract][Full Text] [Related]
16. Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v).
Skowronski DM; Janjua NZ; De Serres G; Purych D; Gilca V; Scheifele DW; Dionne M; Sabaiduc S; Gardy JL; Li G; Bastien N; Petric M; Boivin G; Li Y
J Infect Dis; 2012 Dec; 206(12):1852-61. PubMed ID: 22872731
[TBL] [Abstract][Full Text] [Related]
17. Partial Protection Induced by 2011-2012 Influenza Vaccine Against Serologically Evidenced A(H3N2) Influenza Virus Infections in Elderly Institutionalized People.
Camilloni B; Basileo M; Menculini G; Tozzi P; Iorio AM
Adv Exp Med Biol; 2016; 897():45-53. PubMed ID: 26577530
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Next-Generation H3 Influenza Vaccines in Ferrets Pre-Immune to Historical H3N2 Viruses.
Allen JD; Ross TM
Front Immunol; 2021; 12():707339. PubMed ID: 34475872
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®): an open label, uncontrolled study.
Vinnemeier CD; Fischer-Herr J; Meyer S; Liebig K; Theeß W; Burchard GD; Cramer JP
Hum Vaccin Immunother; 2014; 10(2):441-8. PubMed ID: 24240428
[TBL] [Abstract][Full Text] [Related]
20. Absence of cross-reactive antibodies to influenza A (H1N1) 2009 before and after vaccination with 2009 Southern Hemisphere seasonal trivalent influenza vaccine in children aged 6 months-9 years: a prospective study.
McVernon J; Laurie K; Barr I; Kelso A; Skeljo M; Nolan T
Influenza Other Respir Viruses; 2011 Jan; 5(1):7-11. PubMed ID: 21138535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
